Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07389278 · ClinicalTrials.gov registry record · Phase 1
Combination ADI-PEG 20, TMZ, and RT for Treatment of Newly Diagnosed High-grade Glioma (HGG)
A Phase 1 study, sponsored by Sabine Mueller, MD, PhD.
- Not yet
- Registry status
- Phase 1
- Development phase
- 97
- Enrollment target
NCT07389278 is a Phase 1 study that has not yet begun recruiting, run by Sabine Mueller, MD, PhD. The registered enrollment target is 97 participants.
The verdict
NCT07389278, a Phase 1 study, has not yet begun recruiting, sponsored by Sabine Mueller, MD, PhD.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 97 participants
- Enrollment target
Study Summary
This is an open label, intra-patient dose escalation, to evaluate ADI-PEG 20, in combination with Temozolomide (TMZ) and radiation therapy (RT) in children, adolescents and young adult patients with newly diagnosed high grade glioma (HGG).
Interventions
- DRUG Temozolomide (TMZ)
- DRUG ADI-PEG 20 (Arginine deiminase pegylated)
- RADIATION Standard of Care Radiation Therapy (RT)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 97 participants |
| Start Date | 2026-03-09 |
| Est. Completion | 2035-06-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07389278
The ClinicalTrials.gov registry entry for NCT07389278 describes a study currently listed as not yet recruiting, categorized as Phase 1. The registered enrollment target is 97 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sabine Mueller, MD, PhD, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Temozolomide (TMZ) is the first listed.
NCT07389278 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07389278 about?
NCT07389278 is a clinical study titled "Combination ADI-PEG 20, TMZ, and RT for Treatment of Newly Diagnosed High-grade Glioma (HGG)". This is an open label, intra-patient dose escalation, to evaluate ADI-PEG 20, in combination with Temozolomide (TMZ) and radiation therapy (RT) in children, adolescents and young adult patients with newly diagnosed high grade glioma (HGG).
What is the current status of trial NCT07389278?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 97 participants. The study started on 2026-03-09. Estimated completion is 2035-06-30.
What interventions are being tested in trial NCT07389278?
The interventions under investigation include: Temozolomide (TMZ) (DRUG), ADI-PEG 20 (Arginine deiminase pegylated) (DRUG), Standard of Care Radiation Therapy (RT) (RADIATION).
Who is sponsoring clinical trial NCT07389278?
This trial is sponsored by Sabine Mueller, MD, PhD, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.